Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279059 | 0.78 | GAA (0.51) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL1725699 | 0.72 | MEN1 (0.33) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL9004464 | 0.67 | KMT2A (0.38) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL31213291 | 0.65 | MEN1 (0.36) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL2197848 | 0.65 | MEN1 (0.36) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL4651 | 0.62 | NOX1 (0.59) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL28535050 | 0.61 | NOX1 (0.57) | MEN1GAAMAPTKMT2ANPSR1 | |
| SCHEMBL28860617 | 0.61 | NOX1 (0.52) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL10738447 | 0.60 | GAA (0.42) | MEN1GAAMAPTKMT2APABPC1 | |
| SCHEMBL6313583 | 0.60 | NOX1 (0.46) | MEN1GAAMAPTKMT2APABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10814013-B2 | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2721035-B1 | GLIOBLASTOMA INHIBITING COMPOUNDS AND THEIR USE | LIFE & BRAIN GMBH (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2079486-B1 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | UNIV TEXAS (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9573960-B2 | Glioblastoma inhibiting compounds and their use | LIFE & BRAIN GMBH (DE) | 2017-02-21 | — | — | US | disclosed |
| US-20150148390-A1 | GLIOBLASTOMA INHIBITING COMPOUNDS AND THEIR USE | LIFE & BRAIN GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| CN-103764659-A | Glioblastoma inhibiting compounds and their use | LIFE AND BRAIN GMBH | 2014-04-30 | — | — | CN | disclosed |
| EP-2721035-A1 | GLIOBLASTOMA INHIBITING COMPOUNDS AND THEIR USE | Life & Brain GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-20130039853-A1 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | CELL>POINT, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2012172069-A1 | GLIOBLASTOMA INHIBITING COMPOUNDS AND THEIR USE | LIFE AND BRAIN GMBH (DE) | 2012-12-20 | — | — | WO | disclosed |
| EP-2146632-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | The Board of Regents of The University of Texas System (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2079486-A2 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | The Board of Regents of The University of Texas System (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009004496-A2 | BISANTHRAPYRAZOLES AS ANTI-CANCER AGENTS | UNIVERSITY OF MANITOBA (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008130439-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008045604-A2 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007137190-A2 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2007-05-03 | — | — | US | disclosed |
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-22 | — | — | US | disclosed |
| US-7034043-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | ECPAS, PCNA, MRPS22 | MEN1 2609/4885GAA 946/4885MAPT 3873/4885 |
| US-10814013-B2 | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | TNNI3, CAD, TNNT2 | MEN1 214/4885GAA 36/4885MAPT 3883/4885 |
| US-20130039853-A1 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | TNNI3, CAD, TNNT2 | MEN1 214/4885GAA 36/4885MAPT 3883/4885 |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | ECPAS, PCNA, MRPS22 | MEN1 2609/4885GAA 946/4885MAPT 3873/4885 |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCL, NME4 | MEN1 34/4885GAA 1806/4885MAPT 2081/4885 |
| US-20150148390-A1 | GLIOBLASTOMA INHIBITING COMPOUNDS AND THEIR USE | GMFG, GDI1, GDI2 | MEN1 708/4885GAA 11/4885MAPT 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.